Bio-Rad Laboratories has been a focal point in numerous investment reviews and dialogues. They opened
exclusive investor access during the Jefferies Healthcare Conference with COO Jon DiVincenzo. Although the past performance shows considerable losses, with shares sliding by 28% and three-year losses reportedly reaching 61%, there is speculation on the stock's undervalue because of this drop combined with
low debt. This has led to investors considering whether it's too late to buy. An interesting move is Bio-Rad's proposal to
acquire Stilla, known for its next-gen digital platform in PCR technology which might give a boost. The company also showcased a
steady business, with a stake in Sartorius contributing to long-term value. Notably, Billionaire Mason Hawkins highlighted BIO as a small-cap stock with huge upside potential. However,
Q1 earnings surpassed estimates but with revenues reported as declining, driven by a weak academic research market. Yet, the management has projected
cautious growth for the year 2024. Despite reports stating that BIO's Q4 earnings and revenues missed estimates, the stock rose in aftermarket. However, there seems to be a lack of confidence with regards to their international revenue trends.
Bio-Rad Laboratories Stocks News Analytics from Mon, 13 Feb 2017 08:00:00 GMT to Sat, 31 May 2025 19:38:00 GMT -
Rating -4
- Innovation 2
- Information 6
- Rumor -3
